VLPs: Pioneering Prevention in Infectious Diseases & Cancer

Virus-like Particles (VLPs) bridge nanotechnology, immunology, and synthetic biology, pivotal in preventing and treating infectious diseases and cancer.

With years of CDMO experience, Yaohai Bio-Pharma excels in recombinant protein vaccine development and GMP production, including VLP vaccines. It also explains VLPs' structure, immune response, and cancer protection.

Optimal VLP Structure:

High-polymer antigens can induce stronger immune responses, with a 28nm antigen spacing yielding the best activation effect in B cells.

Antigen Coupling with VLPs:

Modular assembly avoids antigen misfolding, while the SpyTag/SpyCatcher system and its upgraded versions enable efficient coupling. SnoopLigase and DogTag/DogCatcher systems also provide irreversible coupling methods. The coupling of polysaccharides with SpyCatcher significantly enhances antibody responses.

New Structures of VLPs:

Synthetic biology approaches create new VLP structures, such as icosahedral 240-mers, which assemble with antigens from HIV, influenza, etc., enhancing antigen stability.

Adjuvant Role of VLPs:

The intrinsic characteristics of VLPs and their presentation of multimers influence immune responses. Packaging with bacterial RNA can elicit maximal protective effects. As adjuvants, VLPs coupled with photoactivatable drugs can induce antitumor responses.

Interaction between VLPs and Immune Responses:

The protein corona on viruses affects infectivity, while VLP glycosylation enhances immunogenicity, promoting robust immune responses.

Mosaic nanoparticles facilitate the production of antibodies that bind to more pathogen strains. Nanoparticle mosaics show potential against SARS-CoV-2 variants and emerging viruses. Nanopatterning strategies concentrate antibody responses, effectively addressing challenging vaccine targets like Zika virus.

Conclusion:

Technological advancements have made it routine to arrange complex antigens on VLPs, enabling their expansion for clinical development to induce protective antibody responses. Trials targeting viruses such as SARS-CoV-2 will reveal the impact of VLP characteristics on human immunity, offering new hope for the treatment of stubborn infectious diseases and cancer.

Yaohai Bio-Pharma is also actively seeking institutional or individual global partners and offers the most competitive compensation in the industry. If you have any questions, please feel free to contact us: [email protected]